“Our priority is to get an NDA solution for Qtrypta ™,” said Steven Lo, President and CEO of Zosano. “We plan to hold a Type A assembly with the FDA as soon as possible and look forward to getting an explanation of the next steps and the option to resubmit our NDA. We continue to believe in the promise that Qtrypta represents as an attractive option for migraine patients. During the quarter, we entered into a feasibility review agreement with Mitsubishi Tanabe Pharma Corporation that complements the perspective of our formula of transdermal microneedters technology.
Recent updates
Financial effects for the third quarter ended September 30, 2020
Research and progression prices for the third quarter of 2020 were $5. 8 million, compared to $6. 5 million for the same quarter of 2019. The $0. 7 million minimisation was basically due to minimizing clinical trial prices of $0. 8 million due to the final touch. of Zosano’s long-term work, security examination in 2019, a minimum of $0. 2 million in reimbursement prices due to the reduction and a minimum of $0. 3 million in overall and commercial prices due to COVID -19. These minimizations were partially offset by an accumulation of $0. 3 million relevant to the expansion and movement of generation to Zosano’s contract brands and an accumulation in depreciation expense of $0. 3 million similar to assets put into service with its subcontractors.
Overhead and administrative expenses for the 3rd quarter of 2020 were $2. 7 million, compared to $3. 1 million in 2019 The $0. 4 million minimisation was mainly due to a $0. 4 million minimisation in pro-similar prices to strategic and pre-commercial activities and a $0. 2 million minimisation in reimbursement prices similar to staff reduction. These minimizations were partially offset by an accumulation of $0. 2 million in legal and professional prices similar to the problems of corporate and high-level assets and audit fees.
Cash and money equivalents as of September 30, 2020 were $43. 6 million to $6. 3 million as of December 31, 2019.
Zosano Pharma Zosano Pharma Corporation is a clinically phased biopharmaceutical company aimed at product progression in which the immediate management of approved molecules with established efficacy and protection profiles can bring truly broad benefits to patients in markets where patients remain very neglected through existing therapies. Needle formula generation consists of drug-coated titanium microneedlees designed to allow immediate formulated handling of healing products for patients. Zosano’s main candidate product is Qtrypta ™ (M207), which is an exclusive zolmitriptan formula designed to be administered through transdermal microneedle formula generation, as an acute remedy for migraine. Learn more about www. zosanopharma. com or attach it via LinkedIn to https://www. linkedin. com/corporate/zosano-pharma, Twitter at https://twitter. com/ZosanoPharma and Instagram at https://www. instagramArraycom/zosanopharma/.
Zosano Contacts: Christine Matthews CFO 510-745-1200
Zosano PR: Sylvia Wheeler or Alexandra Santosswheeler@wheelhouselsa. com or asantos@wheelhouselsa. com
ZOSANO PHARMA CORPORATION BILAN (thousands, nominal price and number of shares)